At launch, Amgen saw Infergen as clinically equivalent to then-leader Intron-A. They just couldn't come up with a commercial differentiator, rejecting the idea of doing managed care discount deals, for example. Sales went nowhere so Amgen offloaded to a Japanese outfit - Yamanouchi - not ITMN surely? I lost track of the story years ago, but are you saying that the drug was never equivalent to Intron A or simply that the latter is obsolete?
Market Data 
Markets 
AI
